Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123M
-
Number of holders
-
125
-
Total 13F shares, excl. options
-
60M
-
Shares change
-
+937K
-
Total reported value, excl. options
-
$225M
-
Value change
-
-$31.6M
-
Put/Call ratio
-
3.46
-
Number of buys
-
73
-
Number of sells
-
-50
-
Price
-
$3.75
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q4 2019
149 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q4 2019.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 125 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 60M shares
of 123M outstanding shares and own 48.68% of the company stock.
Largest 10 shareholders include BlackRock Inc. (8.44M shares), STATE STREET CORP (7.42M shares), ARMISTICE CAPITAL, LLC (5.1M shares), VANGUARD GROUP INC (4.81M shares), Nuveen Asset Management, LLC (2.15M shares), GOLDMAN SACHS GROUP INC (1.93M shares), PRUDENTIAL FINANCIAL INC (1.77M shares), MARSHALL WACE, LLP (1.57M shares), MANGROVE PARTNERS (1.55M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.5M shares).
This table shows the top 125 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.